ASCLETIS PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.31 HKD | -2.24% |
|
+3.15% | -10.27% |
| 03/04 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
| 03/04 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 6,268 | 2,936 | 2,654 | 2,913 | 4,551 | 1,256 | 1,256 | - |
| Enterprise Value (EV) 1 | 3,095 | -52.72 | -58.27 | 420.5 | 2,084 | -882.5 | -743.9 | -440.2 |
| P/E ratio | - | -29.2 x | -12 x | -14.8 x | -14.5 x | -9.85 x | -6.12 x | -5.46 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 37.7 x | 16.9 x | 75.8 x | 37.9 x | 84.1 x | 24.4 x | - | - |
| EV / Revenue | 18.6 x | -0.3 x | -1.66 x | 5.47 x | 38.5 x | -15.6 x | - | - |
| EV / EBITDA | -23.3 x | 0.28 x | 0.23 x | -1.93 x | -5.58 x | 3.04 x | 2.54 x | 1.44 x |
| EV / FCF | -2,75,35,763 x | 5,65,548 x | - | - | - | - | - | - |
| FCF Yield | -0% | 0% | - | - | - | - | - | - |
| Price to Book | 1.42 x | 0.84 x | 0.84 x | 1.08 x | 1.79 x | - | - | - |
| Nbr of stocks (in thousands) | 11,20,685 | 11,06,336 | 10,98,782 | 10,86,734 | 10,87,134 | 10,12,758 | 10,12,758 | - |
| Reference price 2 | 5.593 | 2.654 | 2.416 | 2.681 | 4.186 | 1.240 | 1.240 | 1.240 |
| Announcement Date | 24/03/19 | 24/03/20 | 30/03/21 | 21/03/22 | 19/03/23 | 25/03/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 166.3 | 173.4 | 35 | 76.88 | 54.09 | 56.6 | - | - |
| EBITDA 1 | -132.7 | -188.7 | -258 | -217.4 | -373.6 | -290.5 | -292.9 | -305.6 |
| EBIT 1 | -144.7 | -210.9 | -285.2 | -246.9 | -403.8 | -308.9 | -309.4 | -320.7 |
| Operating Margin | -86.99% | -121.57% | -814.86% | -321.18% | -746.55% | -545.88% | - | - |
| Earnings before Tax (EBT) 1 | -19.87 | -95.97 | -209.2 | -199 | -314.8 | -144.7 | -186.6 | -193.6 |
| Net income 1 | -7.258 | -95.97 | -209.2 | -199 | -314.8 | -144.7 | -219 | -242.5 |
| Net margin | -4.36% | -55.33% | -597.81% | -258.88% | -582.07% | -255.7% | - | - |
| EPS 2 | - | -0.0910 | -0.2012 | -0.1813 | -0.2896 | -0.1347 | -0.2027 | -0.2273 |
| Free Cash Flow | -112.4 | -93.23 | - | - | - | - | - | - |
| FCF margin | -67.58% | -53.75% | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 24/03/19 | 24/03/20 | 30/03/21 | 21/03/22 | 19/03/23 | 25/03/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S1 | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 75.4 | 98.04 | 31.83 | 3.167 | 36.55 | 40.33 | 38.22 | 15.87 | 46.51 | 10.09 | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | - | - | - | - | - | -80.33 | -228.6 | -177.3 | -194.3 |
| Operating Margin | - | - | - | - | - | - | - | - | -172.73% | -2,265.77% | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | - | -0.0463 | -0.0494 | -0.1518 | -0.1009 | -0.0804 | -0.0810 | -0.2086 | -0.0152 | -0.1195 | -0.1200 | -0.1400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 29/08/19 | 24/03/20 | 28/08/20 | 30/03/21 | 26/08/21 | 21/03/22 | 22/08/22 | 19/03/23 | 22/08/23 | 25/03/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 3,173 | 2,989 | 2,712 | 2,493 | 2,467 | 2,266 | 2,000 | 1,696 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -112 | -93.2 | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | -0.36% | -2.84% | -2.6% | -6.97% | -12% | - | - | - |
| ROA (Net income/ Total Assets) | -0.32% | -1.38% | - | - | - | - | - | - |
| Assets 1 | 2,259 | 6,954 | - | - | - | - | - | - |
| Book Value Per Share | 3.940 | 3.150 | 2.870 | 2.490 | 2.340 | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 15.8 | 18.9 | - | - | - | - | - | - |
| Capex / Sales | 9.51% | 10.89% | - | - | - | - | - | - |
| Announcement Date | 24/03/19 | 24/03/20 | 30/03/21 | 21/03/22 | 19/03/23 | 25/03/24 | - | - |
1CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.24
CNY
Average target price
2.752
CNY
Spread / Average Target
+121.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.27% | 173M | |
| -4.06% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +55.70% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +4.87% | 8.71B |
- Stock Market
- Equities
- 1672 Stock
- Financials Ascletis Pharma Inc.
